Stoke Therapeutics (NASDAQ:STOK) announces quarterly earnings results. October 29, 2026 Key points. * Stoke Therapeutics missed earnings expectations, reporting a quarterly loss of $1.08 per share versus the $0.93 consensus estimate, while revenue of $11.26 million exceeded expectations of $8.21 million. * The EMPEROR Phase III trial remains on schedule, with topline data still expected in the third quarter of 2027. The FDA also agreed to a multicomponent Vineland-3 assessment for the planned U.S. application. * Stoke ended the quarter with $358.8 million in cash and marketable securities, which management expects to support operations into early 2028, including preparations for a potential early-2028 zorevunersen launch. * Interested in Stoke Therapeutics? Here are five stocks we like better. Stoke Therapeutics (NASDAQ:STOK - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.15), FiscalAI reports. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The company had revenue of $11.26 million for the quarter, compared to the consensus estimate of $8.21 million. Here are the key takeaways from Stoke Therapeutics' conference call: * EMPEROR Phase III remains on track: Approximately 110 of 162 patients have reached the week 28 primary endpoint visit, about 20 have completed the 52-week treatment period, and no patients have discontinued treatment. Stoke continues to expect topline data in Q3 2027. * The FDA agreed that Stoke may use a multicomponent Vineland-3 assessment covering four cognitive and behavioral subdomains for the planned U.S. NDA. Management believes this approach better reflects Dravet syndrome's variability and improves statistical power; the company does not currently anticipate an advisory committee meeting. * Stoke is advancing its potential commercial launch of zorevunersen, estimating approximately 6,000 immediately addressable U.S. pediatric patients and increasing awareness among treatment centers, payers, and neurologists. The company is preparing patient services, market access, and treatment-site infrastructure for a potential launch in early 2028. * The STK-002 program for autosomal dominant optic atrophy is progressing, with dosing underway in the third OSPREY cohort and a fourth cohort expected to begin in early 2027. Initial safety and efficacy data from higher-dose cohorts are anticipated in the first half of 2027. * Stoke ended the quarter with $358.8 million in cash, cash equivalents, and marketable securities, while reporting a quarterly net loss of $73.6 million. Including expected Biogen reimbursements and a potential development milestone, management expects its cash position to fund operations into early 2028. Stoke Therapeutics stock performance. Stoke Therapeutics stock traded down $0.06 during mid-day trading on Thursday, reaching $26.35. The company's stock had a trading volume of 1,879,613 shares, compared to its average volume of 821,787. The company has a market capitalization of $1.70 billion, a P/E ratio of -7.89 and a beta of 1.26. Stoke Therapeutics has a 12-month low of $20.32 and a 12-month high of $40.22. The firm's fifty day moving average price is $27.66 and its two-hundred day moving average price is $30.94. Analyst ratings changes. Several research firms have commented on STOK. Canaccord Genuity Group decreased their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. Wedbush boosted their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th. Guggenheim reaffirmed a "buy" rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Finally, JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a report on Friday, August 21st. They set an "overweight" rating and a $40.00 price target on the stock. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $44.25. Discover more MarketBeat All Access MarketBeat Research Tools Insider buying and selling at Stoke Therapeutics. In other news, insider Barry Ticho sold 7,176 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider directly owned 20,422 shares in the company, valued at $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Edward Kaye sold 12,567 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the transaction, the director owned 124,557 shares of the company's stock, valued at $3,989,560.71. This trade represents a 9.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 34,594 shares of company stock valued at $1,069,305 in the last quarter. 9.60% of the stock is currently owned by corporate insiders. Stoke Therapeutics company profile. Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke's leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Stoke Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list. While Stoke Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Continue following MarketBeat

Stoke Therapeutics (Nasdaq: STOK) granted stock options to 18 new employees on October 15, 2026, as an incentive to join the company. The Bedford, Massachusetts, biotech said the grants comply with Nasdaq Listing Rule 5635(c)(4). Stephen Aschettino, its newly appointed senior vice president and chief information officer, received options to buy 70,000 shares. Seventeen other new hires received options for a combined 175,920 shares. The exercise price is $24.61 per share, the closing price on October 15, 2026. The options vest over four years, with a quarter vesting after one year and the rest monthly over the following 36 months. They run for 10 years under the 2023 Inducement Plan. Stoke is developing zorevunersen, an RNA medicine for Dravet syndrome, in a Phase 3 study.

Stoke brings STK-002 to AAO as evidence takes center stage. Stoke's STK-002 presentations will focus attention on the evidence for its investigational optic atrophy medicine, not establish a treatment breakthrough. Key facts. * Company and market snapshot: STOK: 24.36, currency and exchange unspecified in supplied data; down 3.79% as of October 6, 2026, 18:37:37 GMT. * Investigational medicine: STK-002, described by Stoke Therapeutics as an investigational treatment. * Intended condition: Autosomal dominant optic atrophy, abbreviated ADOA. * Scientific meeting: Presentations announced for the American Academy of Ophthalmology's 2026 Annual Meeting. Stoke Therapeutics announced presentations of STK-002, its investigational medicine for autosomal dominant optic atrophy, at the American Academy of Ophthalmology's 2026 Annual Meeting. Stoke Therapeutics (STOK) announced presentations of STK-002, an investigational medicine for autosomal dominant optic atrophy, at the American Academy of Ophthalmology's 2026 Annual Meeting. The development brings the candidate before an eye-care audience, but the announcement alone does not establish whether it improves vision or changes the course of the disease. The distinction matters for patients, clinicians and investors. A conference presentation can provide a setting for evaluating research; it is not itself a clinical success or a regulatory decision. The central question is what the presentations will show about STK-002 and how much that evidence can support. Stoke's announcement identifies the medicine, the intended condition and the meeting, according to Business Wire. The available details do not specify presentation findings, study design, patient results or a regulatory timetable. Those limits make this a research-development story rather than a report of demonstrated treatment benefit. What the AAO announcement establishes. STK-002 is being developed for autosomal dominant optic atrophy, abbreviated ADOA. The company describes it as investigational, meaning it remains under study rather than being established by this announcement as an approved treatment. Nothing in the supplied information supports a claim about its effectiveness, safety profile or readiness for commercial use. The American Academy of Ophthalmology meeting provides a specialist setting for the presentations. That is relevant because research aimed at an eye condition needs scrutiny not only of its scientific rationale but also of how its findings relate to visual function and clinical practice. Still, the setting should not be confused with the strength of the evidence. The announcement does not identify whether the presentations concern laboratory work, patient observations or another type of research. It would therefore be premature to describe them as a clinical-trial readout or to assign the program a development stage. For now, the concrete development is that Stoke plans to present work on the candidate. The next useful information will be the content of that work: what was investigated, how it was measured and what conclusions the results can reasonably support. The evidence questions that matter for STK-002. Any assessment should begin by distinguishing a biological effect from a benefit that matters to patients. Evidence that an investigational medicine influences a disease-related process can be important, but it does not automatically show that people see better, retain vision longer or experience improved daily functioning. If patient findings are presented, the methods will matter alongside the results. Readers should look for an explanation of who was studied, what outcomes were measured and whether the research included a comparison that helps separate a treatment effect from other influences. These are evaluation questions, not details confirmed for STK-002. The observation period would also affect interpretation. A result measured soon after treatment may answer a different question from one tracked over a longer interval. Without that information, it is difficult to assess whether an apparent effect is sustained or whether the research addresses the disease's course. A result measured soon after treatment may answer a different question from one tracked over a longer interval. Safety requires its own examination. A favorable biological finding cannot substitute for information about unwanted effects, tolerability or the practical demands of treatment. The available announcement supplies no basis for concluding that STK-002 is safe, unsafe or preferable to another approach. The most useful presentation would connect the scientific claim to the evidence supporting it while making the limitations clear. That means separating observed results from hypotheses and explaining what further work would be needed before a treatment claim could be established. Shares fall, but the cause is not established. Stoke's shares were down 3.79% on the day at the last-trade timestamp of October 6, 2026, at 18:37:37 GMT, according to the supplied licensed market data. The quote is an intraday snapshot, not a closing result. The decline occurred while the supplied broad-market benchmarks were positive. The S&P 500 benchmark was up 0.65%, the Nasdaq 100 benchmark was up 0.57%, and the Dow benchmark was up 0.50%. That contrast shows Stoke moving against the broader market direction at the stated time. It does not establish why the shares fell. The information supplied contains no investor commentary, trading-volume context or presentation results that would link the move to a particular scientific judgment. Calling the decline a rejection of STK-002 would go beyond the evidence. Investors should keep the trading signal and the research signal separate. A share-price change captures market activity at a moment in time. The candidate's scientific value depends on evidence that the presentation announcement does not yet describe. Neither the conference appearance nor the stock decline resolves the other. What patients and investors should watch next. For patients and families, the immediate distinction is between research visibility and treatment availability. This announcement does not establish access to STK-002 or provide a basis for changing care. Decisions about an investigational medicine require clinical information and guidance beyond a conference notice. For clinicians, the substantive material will be the methods and findings behind the presentations. For investors, it will also matter whether those findings clarify the program's next development steps. The available information does not support a launch forecast, a revenue estimate or a prediction about regulatory action. The next assessment should therefore focus on the presentation materials and any supporting evidence Stoke makes available. Until then, STK-002 has a defined intended use and an announced scientific forum, but not a demonstrated outcome in the facts supplied here. The meeting's value will rest on how much uncertainty the research can actually reduce. Frequently asked questions. What did Stoke Therapeutics announce about STK-002? Stoke Therapeutics announced presentations of STK-002 at the American Academy of Ophthalmology's 2026 Annual Meeting. The company describes the candidate as an investigational medicine for autosomal dominant optic atrophy. The supplied announcement details do not identify specific findings, patient outcomes, study methods or a regulatory timetable. Is STK-002 an approved treatment for ADOA? The announcement describes STK-002 as investigational, not as an approved treatment for autosomal dominant optic atrophy. A conference presentation does not itself establish regulatory approval, clinical benefit or treatment availability. The supplied information provides no basis for patients to change care or assume that the medicine is commercially available. Does the announcement show that STK-002 improves vision? No vision results are included in the supplied facts. The announcement establishes that presentations are planned, not that STK-002 improves vision or changes disease progression. Assessing those claims would require the actual findings, the measurements used, the study methods and an explanation of the research's limitations. What should readers look for in the presentations? Readers should look for the type of research presented, the methods used and the outcomes measured. If patient results are included, comparison methods, follow-up and safety information will be important. A biological effect should be distinguished from a demonstrated benefit in vision or daily functioning; neither is established by the announcement. How were Stoke shares trading after the announcement? The supplied licensed market data showed STOK down 3.79% on the day as of October 6, 2026, at 18:37:37 GMT. This was an intraday snapshot, not a closing result. The available information does not establish that the presentation announcement caused the decline or reveal investors' reasoning. What does the AAO presentation mean for investors? The presentation offers an opportunity to examine research on STK-002, but its investment significance depends on the evidence disclosed. Investors should assess whether the findings clarify benefit, safety and further development needs. The announcement alone does not support a commercial forecast, a regulatory prediction or a valuation conclusion.